This is the authors' abstract. We don't add key points for this paper.
Hematopoietic stem cells (HSCs) are a rare but critical cell population in hematopoietic system health, pathology, and therapy1. This self-renewing multipotent stem cell population primarily resides in the bone marrow, where they sustain life-long blood production. HSCs are now understood to be a common origin of hematological dysfunction, with acquisition of genetic mutations in HSCs being an initiating event for myeloid leukemias and myelodysplastic syndromes. Mutant HSCs also drive clonal hematopoiesis, which represents a risk factor for a range of hematological and non-hematological pathologies2. Therapeutically, allogeneic and autologous stem cell transplantation rely on the regenerative potential of HSCs and represent a mainstay treatment for many of the most serious hematological diseases. HSC gene therapies also leverage this regenerative capacity, with gene correction HSC products now approved for several hematological disorders.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Wilkinson et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: